PATENT CLAIM ANALYSIS

Application Number: 15992957
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-04
Patent Classification: ["514", "427000"]

Abstract:
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

Claim (Index 37):
A pharmaceutical composition comprising:\n a) a compound of formula (I) wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg;\n b) a buffering agent; \n c) a stabilizer; \n d) optionally a second therapeutic agent; and \n e) optionally one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 93.0
- Lexical Diversity: 1.23404
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15345035', '13978791', '12239708', '12239697', '10969463']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7650172731562513
- 35 USC 102 Novelty (BERT): 0.5470510621705833
- Combined Prediction Score: 0.7432206520576846
- Mean Citation Score: 292.809004
- Max Citation Score: 415.3839
- Similarity Product: 336.35709678322075

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test